# Rivaroxaban in Thrombotic Antiphospholipid Syndrome

> **NCT02157272** · PHASE3 · TERMINATED · sponsor: **University of Padova** · enrollment: 121 (actual)

## Conditions studied

- Antiphospholipid Syndrome

## Interventions

- **DRUG:** Experimental: Rivaroxaban

## Key facts

- **NCT ID:** NCT02157272
- **Lead sponsor:** University of Padova
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2018-01-25
- **Final completion:** 2018-01-25
- **Target enrollment:** 121 (ACTUAL)
- **Why stopped:** Unbalance in the composite endpoint between arms.
- **Last updated:** 2018-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02157272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02157272, "Rivaroxaban in Thrombotic Antiphospholipid Syndrome". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02157272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*